Designed for added convenience and flexibility.
Introducing the new DIPRIVAN
®
(Propofol) Injectable Emulsion,
USP 10 mL vial for single-patient infusion, available exclusively
from Fresenius Kabi. It's just one of the ways we innovate to
stay in the lead.
For ordering details and prescribing information,
visit www.diprivan10mL.com
Safety Information
DIPRIVAN Injectable Emulsion is contraindicated in patients with a known hypersensitivity to DIPRIVAN Injectable Emulsion or any of its
components, and also in patients with allergies to eggs, egg products, soybeans or soy products. Use of DIPRIVAN Injectable Emulsion has been
associated with both fatal and life-threatening anaphylactic and anaphylactoid reactions, as well as Propofol Infusion Syndrome. For general
anesthesia or MAC sedation, DIPRIVAN Injectable Emulsion should be administered only by persons trained in the administration of general
anesthesia and not involved in the conduct of the surgical/diagnostic procedure. For sedation of intubated, mechanically ventilated patients in
the ICU, DIPRIVAN Injectable Emulsion should be administered only by persons skilled in the management of critically ill patients and trained in
cardiovascular resuscitation and airway management. Sedated patients should be continuously monitored. Strict aseptic technique must always
be maintained during handling. DIPRIVAN Injectable Emulsion is a single access parenteral product. Failure to use aseptic technique has been
associated with microbial contamination of the product, including fever, infection/sepsis, other life-threatening illness and/or death. There have
been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV)
from unsafe injection practices, and use of Propofol vials intended for single use on multiple persons. DIPRIVAN Injectable Emulsion vials are
never to be accessed more than once or used on more than one person.
0742-DIP-05-08/14
